Allison Fitzgerald, Hematology/Oncology Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Today I learned that the current thinking for resistance to antibody-drug conjugates (ADCs) is that resistance is more likely to the payload than the target, so it might be possible that a second ADC targeting the same thing but with a different payload would be effective!”
More posts featuring Allison Fitzgerald.